 Thank you, Jeff, and thank you all again for coming. As Jeff and Rex mentioned, the meeting that we had in June was pulled together on an equally short timeframe, but also was considerably smaller. And one of the things that we're trying to do is to expand this field and disseminate more. We'll find a bigger room, hopefully one that's not quite so warm. We are working on that. But we really do need your advice, and I think a good chunk of tomorrow we'll be asking you basically, you know, what's the best way for us all to interact? So let's see. So yes, so the outcomes that we had anticipated and that I think have come to fruition just in the few months since then were sort of an enhanced appreciation and understanding of ongoing efforts because as Eric and Rex mentioned, there really was some doubt as to whether genomic medicine was sort of ready. But NIH-wide, we have representatives from multiple institutes now recognizing the importance of this. Also some writing groups either for perspectives or best practice guidelines. We do have a manuscript in draft from the June meeting. And we've distributed the tables and the figure from that. We thought that would be sort of the most useful rather than having the whole text which is probably gonna change somewhat. We could also develop some planning groups for workshops or conferences. And again, as Jeff said, we're looking for kind of a loose or maybe a tighter but a loose confederation or consortium for collaborative studies. And that's really the main thing here. Guidelines tends to be kind of a difficult word to some folks so maybe we'll just call them best practices that we can opine on and then let others decide what guidelines should be. As Jeff mentioned, we had over 20 centers at varying stages of implementation in June supported through multiple NIH but primarily institutional mechanisms. There were, it seemed to us, numerous similar and overlapping efforts that really would benefit from collaboration and a lot of shared needs that we're trying to address by these subsequent meetings. We thought that would benefit from periodic interactions in some degree of coordination but we wanna be sure that we facilitate and unlike many government efforts, not impede things. So our proposed goals were to identify research directions and priorities, promote collaboration among existing groups which is the focus of the meeting today, stimulate investigator initiated efforts and we can issue funding solicitations but as Eric said, things are a little bit grim this year so we can't do 20 of them and we don't even know if we can do one but we're keeping our fingers crossed. We'd like amongst our staff, both NHGRI and NIH to learn more about the genomic medicine centers that are out there and what y'all are doing and to the extent that you're nearby and we can drive or walk, we can visit or find other ways to get out there and then establishes Eric described a genomic medicine working group as a subcommittee of our council which gives it sort of an official status. It would have a rotating membership area or will much like many of our advisory groups so that we get a continued influx of folks who can give us advice. We'd need to have one active council member and a report back to council regularly. This group will identify topics for subsequent meetings. We meet about once a month or so by phone, topics for separate working groups, monitor production of white papers and maybe stimulate people to get things done as needed and then also sort of maybe break off and review progress in a given area for whether it's ready to be explored in subsequent groups, reviewing progress overall and identifying related efforts and integrate them as appropriate. And there are a number of them listed here. ClinVar is an NCBI database. You'll hear much more about that from Mark in a moment. Emerge is an NHGRI funded project which you'll probably be hearing about and several of the Emerge PIs are here today. Clinical sequencing exploratory program is a new project that Brad Ozenberger, sitting in the corner next to Mark, is leading and that will be initiated within the next month or so, Brad. Is that right? Tomorrow. Tomorrow even, huh? Yes, come back for that meeting. And TransNIH, a dissemination network that again you'll hear about from Mark and obviously the Clinical Translational Science Awards and something else that's quite relevant. So we had the Databases in Actionable Variance working group on December 1st and 2nd, just this last week. This meeting is on collaborative demonstration projects. We're anticipating that the May meeting will focus on standardization, quality control of clinical genomic testing and reporting. So how does one get these results? That was what was proposed and that seems to be sort of the thing on the horizon. But the outcome of today and tomorrow may be that we changed the idea for this and I know Dan is a flexible guy and so that shouldn't be a problem if we decide that there's something else or in addition that we wanna focus on. We are hoping to have another meeting in September, not decided yet where, but hopefully on the West Coast in sort of fairness to kind of move this across the country. That could be on evidence development. We've heard that there's a lot of need for evidence on what you can actually take action on and that might be an appropriate thing for that September meeting to do. Again, we'd like to sort of have some input on that. There are additional needs for evidence development for the effectiveness of this. So does it actually make a difference in patient care? There are tools that are needed, clinical decision support, clinical algorithms both for treating but also for phenotype assessment and other aspects or policy needs that may be substantial as time goes by. Education, training, user support, sort of the usual sorts of things. We don't wanna have so many meetings though. This is a Larson cartoon. Oh man, the coffee's cold. They thought of everything. And so we don't want to get you guys just doing nothing but coming to meetings. So again, appropriate balance of timing and intensity and attendance would be helpful to get advice on. And then you've already heard sort of about the goals of this meeting. You'll be hearing a little bit later about where we're going to break out into. There are various rooms around here. And the purpose really of the sessions before that is to introduce to you projects that are open to collaboration that are interested in perhaps having some broader reach. So after hearing those presentations then we may sort of take a show of hands of folks who are interested in going to this group so we know which rooms to assign you to just for in terms of size and that. And I think that's pretty much all I had. So Mark, I think you're the next. Any questions for me?